Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$4.97 - $7.49 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$5.85 - $9.51 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

BUY
$4.89 - $8.3 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024

BUY
$2.66 - $6.76 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023

BUY
$2.04 - $2.94 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

BUY
$2.04 - $2.94 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023

BUY
$1.64 - $4.85 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$1.66 - $3.32 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$1.49 - $3.33 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$2.62 - $4.39 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$1.65 - $3.58 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$2.8 - $5.4 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

BUY
$4.5 - $9.05 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021

BUY
$6.17 - $13.48 $0 - $0
0 New
0 $0

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $78M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.